[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201071232A1 - Триазины как ингибиторы киназы pi3 и mtor - Google Patents

Триазины как ингибиторы киназы pi3 и mtor

Info

Publication number
EA201071232A1
EA201071232A1 EA201071232A EA201071232A EA201071232A1 EA 201071232 A1 EA201071232 A1 EA 201071232A1 EA 201071232 A EA201071232 A EA 201071232A EA 201071232 A EA201071232 A EA 201071232A EA 201071232 A1 EA201071232 A1 EA 201071232A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
mtor
disclosed
triazins
kinase inhibitors
Prior art date
Application number
EA201071232A
Other languages
English (en)
Other versions
EA020317B1 (ru
Inventor
Аранапакам М. Венкатесан
Чзэчэн Чэнь
Кристоф М. Денхардт
Освальдо Дос Сантос
Сантос Эфрен Гийермо Делос
Ари Заск
Ерун К. Верхейен
Джошуа Аарон Каплан
Дэвид Дж. Ричард
Семирамис Аирал-Калоустиан
Тарек С. Мансур
Ариамала Гопалсами
Кевин Дж. Каррэн
Мэнсяо Ши
Original Assignee
УАЙТ ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by УАЙТ ЭлЭлСи filed Critical УАЙТ ЭлЭлСи
Publication of EA201071232A1 publication Critical patent/EA201071232A1/ru
Publication of EA020317B1 publication Critical patent/EA020317B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Раскрываются соединения формулы I (I), где Rпредставляет собой (II) или (III) и R, Rи Rимеют значения, указанные в данном описании, и их фармацевтически приемлемые соли и сложные эфиры. Указанные соединения ингибируют киназу PI3 и mTOR и могут использоваться для лечения заболеваний, опосредуемых киназой PI3 и mTOR, таких как различные онкозаболевания. Раскрываются способы получения и применения соединений по данному изобретению. Также раскрываются различные композиции, содержащие соединения по данному изобретению.
EA201071232A 2008-05-23 2009-05-21 ТРИАЗИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ PI3 И mTOR EA020317B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5566108P 2008-05-23 2008-05-23
PCT/US2009/044774 WO2009143313A1 (en) 2008-05-23 2009-05-21 Triazine compounds as p13 kinase and mtor inhibitors

Publications (2)

Publication Number Publication Date
EA201071232A1 true EA201071232A1 (ru) 2011-06-30
EA020317B1 EA020317B1 (ru) 2014-10-30

Family

ID=40911929

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071232A EA020317B1 (ru) 2008-05-23 2009-05-21 ТРИАЗИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ PI3 И mTOR

Country Status (44)

Country Link
US (8) US8039469B2 (ru)
EP (3) EP2294072B1 (ru)
JP (2) JP4948677B2 (ru)
KR (1) KR101331341B1 (ru)
CN (2) CN102036995B (ru)
AP (2) AP2010005452A0 (ru)
AR (2) AR071908A1 (ru)
AU (2) AU2009248997A1 (ru)
BR (1) BRPI0912294B8 (ru)
CA (2) CA2721692C (ru)
CL (2) CL2009001273A1 (ru)
CO (1) CO6311070A2 (ru)
CR (1) CR11757A (ru)
CU (1) CU23887B1 (ru)
CY (2) CY1118879T1 (ru)
DK (2) DK3216793T3 (ru)
DO (1) DOP2010000315A (ru)
EA (1) EA020317B1 (ru)
EC (2) ECSP10010624A (ru)
ES (2) ES2625467T3 (ru)
GE (1) GEP20125589B (ru)
HK (2) HK1157328A1 (ru)
HR (2) HRP20170637T1 (ru)
HU (1) HUE043331T2 (ru)
IL (2) IL209060A (ru)
LT (2) LT3216793T (ru)
MA (1) MA32319B1 (ru)
ME (1) ME01111B (ru)
MX (1) MX2010012808A (ru)
MY (1) MY155653A (ru)
NI (1) NI201000198A (ru)
NZ (1) NZ588526A (ru)
PA (2) PA8828101A1 (ru)
PE (2) PE20091943A1 (ru)
PL (1) PL3216793T3 (ru)
PT (2) PT3216793T (ru)
RS (2) RS58724B1 (ru)
SA (1) SA109300314B1 (ru)
SI (2) SI2294072T1 (ru)
TR (1) TR201906123T4 (ru)
TW (2) TW201008949A (ru)
UA (1) UA99361C2 (ru)
WO (2) WO2009143317A1 (ru)
ZA (1) ZA201007204B (ru)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58724B1 (sr) * 2008-05-23 2019-06-28 Wyeth Llc Jedinjenja triazina kao inhibitori pi3 kinaze i mtor
MY155535A (en) 2008-05-23 2015-10-30 Novartis Ag Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors
US10022381B2 (en) * 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
JP5766177B2 (ja) 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US20130035326A1 (en) * 2009-08-19 2013-02-07 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
WO2011087812A1 (en) * 2009-12-21 2011-07-21 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same
WO2011109833A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US9481670B2 (en) * 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
CA2825825A1 (en) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
BR112013020329A2 (pt) * 2011-02-09 2016-08-02 Hoffmann La Roche compostos heterocíclicos como inibidores da pi3-quinase
SG193982A1 (en) 2011-03-28 2013-11-29 Mei Pharma Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
CN102887867B (zh) * 2011-07-21 2015-04-15 中国科学院上海药物研究所 一类三嗪类化合物、该化合物的制备方法及其用途
AU2012311458B2 (en) 2011-09-21 2016-02-04 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mTOR inhibitors
AU2012320465B2 (en) 2011-10-07 2016-03-03 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
CN102659765B (zh) * 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
KR20160027218A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
WO2014005182A1 (en) * 2012-07-04 2014-01-09 Monash University Phosphoinositide 3-kinase (pi3k) inhibitors
WO2014016849A2 (en) * 2012-07-23 2014-01-30 Sphaera Pharma Pvt. Ltd. Novel triazine compounds
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
SG11201607645TA (en) 2014-03-14 2016-10-28 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
EP3201174A4 (en) * 2014-10-03 2018-06-06 The Royal Institution for the Advancement of Learning / McGill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
KR20170058432A (ko) * 2014-10-10 2017-05-26 화이자 인코포레이티드 상승 효과적 아우리스타틴 조합
EP3221307B1 (en) 2014-11-20 2019-07-24 Council of Scientific & Industrial Research Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof
RU2672875C1 (ru) 2014-12-17 2018-11-20 Пфайзер Инк. Композиции PI3K/MTOR-ингибитора для внутривенного введения
CN104725361B (zh) * 2015-04-09 2017-05-31 江苏富比亚化学品有限公司 一种受阻胺类光稳定剂3346的制备方法
CA3023854A1 (en) 2016-05-12 2017-11-16 Nanjing Shiqi Pharmaceutical Co. Ltd. Novel 2,4,6-trisubstituted s-triazine compounds, preparation method therefor, and use thereof
JP6991158B2 (ja) 2016-05-18 2022-02-10 ピクール セラピューティクス アーゲー 神経障害の治療法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
IT201700047189A1 (it) * 2017-05-02 2018-11-02 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
KR20200009088A (ko) 2017-05-23 2020-01-29 메이 파마, 아이엔씨. 병용 요법
AU2018318129A1 (en) 2017-08-14 2020-03-26 Mei Pharma, Inc. Combination therapy
WO2019038657A1 (en) * 2017-08-25 2019-02-28 Pfizer Inc. AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING 1- (4 - {[4- (DIMETHYLAMINO) PIPERIDIN-1-YL] CARBONYL} PHENYL) -3- [4- (4,6-DIMORPHOLIN-4-YL-1,3,5) triazin-2-yl) phenyl] urea
CN108191837A (zh) * 2018-01-10 2018-06-22 贵州医科大学 PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
KR102022323B1 (ko) * 2018-03-30 2019-09-18 정하윤 트리아진 화합물 및 이의 용도
BR112020023891A2 (pt) 2018-06-07 2021-02-09 Pfizer Inc. formulação aquosa compreendendo 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureia
DK3813946T3 (da) 2018-06-15 2024-08-19 Janssen Pharmaceutica Nv Rapamycin-analoger og anvendelser deraf
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN109942562B (zh) * 2019-02-27 2022-02-08 江西科技师范大学 含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用
CA3163680A1 (en) 2019-12-05 2021-06-10 David John O'neill Rapamycin analogs and uses thereof
CA3179538A1 (en) * 2020-04-07 2021-10-14 Mei Pharma, Inc. Preparation of a 1,3,5-triazinyl benzimidazole
KR20220138575A (ko) 2021-04-06 2022-10-13 부산대학교병원 전좌 신장암 치료 또는 예방용 약물 스크리닝 방법
CN113200969B (zh) * 2021-05-19 2022-11-25 中国药科大学 一种PI3Kα选择性抑制剂及其制备方法和应用
KR20240040768A (ko) 2021-07-26 2024-03-28 셀퀴티 인크. 암의 치료에 사용하기 위한 1-(4-｛[4-(디메틸아미노)피페리딘-1-일]카르보닐｝페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물
CN115109049B (zh) * 2022-08-12 2023-08-15 江西科技师范大学 含芳基脲结构的三嗪类化合物及其应用
CN115557908B (zh) * 2022-09-28 2024-10-15 九江学院 一种含硫连接键的三嗪类衍生物及其合成方法、用途
CN116102545A (zh) * 2023-02-01 2023-05-12 贵州医科大学 一种二芳基脲类PI3K/mTOR/HDAC多靶点抑制剂及其药物组合物和应用
CN116239580A (zh) * 2023-03-06 2023-06-09 中国药科大学 三嗪类化合物及其制备方法、药物组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020462B1 (en) * 1997-07-24 2004-02-11 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agent containing the same as active ingredient
JP2002542144A (ja) * 1997-12-12 2002-12-10 アボット・ラボラトリーズ トリアジン系血管形成阻害剤
US7071189B2 (en) 2001-04-27 2006-07-04 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
CA2599320A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
KR101435231B1 (ko) 2006-08-24 2014-10-02 아스트라제네카 아베 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체
RS58724B1 (sr) * 2008-05-23 2019-06-28 Wyeth Llc Jedinjenja triazina kao inhibitori pi3 kinaze i mtor

Also Published As

Publication number Publication date
EP2294072A1 (en) 2011-03-16
PT3216793T (pt) 2019-05-30
MA32319B1 (fr) 2011-05-02
SA109300314B1 (ar) 2012-09-26
PA8828101A1 (es) 2009-12-16
CA2721710A1 (en) 2009-11-26
ECSP10010623A (es) 2010-12-30
HK1203199A1 (en) 2015-10-23
HK1157328A1 (en) 2012-06-29
JP2011520979A (ja) 2011-07-21
IL209060A0 (en) 2011-01-31
US8445486B2 (en) 2013-05-21
AU2009248993B2 (en) 2011-07-07
EP2294072B1 (en) 2017-03-29
UA99361C2 (ru) 2012-08-10
US20090304692A1 (en) 2009-12-10
DK2294072T3 (en) 2017-05-15
IL209061A0 (en) 2011-01-31
BRPI0912294A2 (pt) 2015-10-20
CN104230831B (zh) 2016-08-24
KR101331341B1 (ko) 2013-11-19
RS58724B1 (sr) 2019-06-28
DOP2010000315A (es) 2010-12-15
US8039469B2 (en) 2011-10-18
GEP20125589B (en) 2012-07-25
NI201000198A (es) 2011-05-09
TWI389906B (zh) 2013-03-21
AU2009248993A1 (en) 2009-11-26
TR201906123T4 (tr) 2019-05-21
CY1121699T1 (el) 2020-07-31
KR20110002485A (ko) 2011-01-07
ECSP10010624A (es) 2010-12-30
PE20091957A1 (es) 2009-12-30
CU20100229A7 (es) 2011-11-15
BRPI0912294B8 (pt) 2021-05-25
RS55960B1 (sr) 2017-09-29
CN104230831A (zh) 2014-12-24
AP2010005452A0 (en) 2010-12-31
US20130005723A1 (en) 2013-01-03
PA8828201A1 (es) 2009-12-16
PE20091943A1 (es) 2009-12-19
CL2009001273A1 (es) 2009-11-27
CR11757A (es) 2010-11-30
US8217036B2 (en) 2012-07-10
US20130315865A1 (en) 2013-11-28
US8575159B2 (en) 2013-11-05
AU2009248997A1 (en) 2009-11-26
MX2010012808A (es) 2010-12-21
CL2009001274A1 (es) 2009-10-16
EA020317B1 (ru) 2014-10-30
HRP20190680T1 (hr) 2019-06-14
ES2625467T3 (es) 2017-07-19
MY155653A (en) 2015-11-13
US8859542B2 (en) 2014-10-14
HUE043331T2 (hu) 2019-08-28
US20140248239A1 (en) 2014-09-04
AR071908A1 (es) 2010-07-21
BRPI0912294B1 (pt) 2019-11-12
PT2294072T (pt) 2017-05-29
SI3216793T1 (sl) 2019-06-28
US9174963B2 (en) 2015-11-03
ME01111B (me) 2013-03-20
IL209060A (en) 2014-05-28
CA2721692C (en) 2014-01-14
JP4948677B2 (ja) 2012-06-06
ES2728163T3 (es) 2019-10-22
HRP20170637T1 (hr) 2017-06-30
AP2010005453A0 (en) 2010-12-31
PL3216793T3 (pl) 2019-09-30
LT2294072T (lt) 2017-06-12
CN102036995A (zh) 2011-04-27
US20090291079A1 (en) 2009-11-26
ZA201007204B (en) 2011-12-28
JP2011522802A (ja) 2011-08-04
US20150011752A1 (en) 2015-01-08
CU23887B1 (es) 2013-04-19
SI2294072T1 (sl) 2017-05-31
LT3216793T (lt) 2019-05-10
EP3216793B1 (en) 2019-03-27
CO6311070A2 (es) 2011-08-22
AU2009248993C1 (en) 2013-10-03
DK3216793T3 (da) 2019-05-06
WO2009143317A1 (en) 2009-11-26
AR071909A1 (es) 2010-07-21
EP3216793A1 (en) 2017-09-13
US20130109670A1 (en) 2013-05-02
CN102036995B (zh) 2014-09-17
CY1118879T1 (el) 2018-01-10
TW201011010A (en) 2010-03-16
US8748421B2 (en) 2014-06-10
NZ588526A (en) 2012-08-31
TW201008949A (en) 2010-03-01
EP2300483A1 (en) 2011-03-30
CA2721692A1 (en) 2009-11-26
AP2775A (en) 2013-09-30
US20110312955A1 (en) 2011-12-22
WO2009143313A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
EA201071232A1 (ru) Триазины как ингибиторы киназы pi3 и mtor
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
EA201001687A1 (ru) Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
EA200802288A1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
EA201000615A1 (ru) Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
MY159615A (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
NO20084435L (no) C-MET proteinkinaseinhibitorer
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
MX2012013197A (es) Inhibidores de indazol de cinasa.
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2009013077A (es) Derivados dde benzoxazolona.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA201000484A1 (ru) Тиенопиримидиновые и пиразолопиримидиновые соединения и их применение в качестве ингибиторов киназы mtor и киназы pi3
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.